По-русски  

Novosibirsk Institute of Nuclear Physics to supply equipment for first commercial nuclear fusion reactor

 09/4/2013, 01:45
related tags
Novosibirsk Institute of Nuclear Physics to supply equipment for first commercial nuclear fusion reactor
Model of the ITER fusion reactor, photo from www.iter.org

The Novosibirsk Institute of Nuclear Physics will supply equipment for the first-ever commercial nuclear fusion reactor, which is being built in France. An agreement has been signed in Novosibirsk with the international organisation ITER (International Thermonuclear Experimental Reactor), reports Sib.fm's correspondent from the agreement signing ceremony on 26 August.

ITER Director-General Professor Osamu Motojima was in Novosibirsk to sign an agreement with Anatoly Krasilnikov, director of the Russian ITER Agency. According to Krasilnikov, the Institute of Nuclear Physics will manufacture equipment for a number of the reactor's diagnostic systems.

The Russian Federation, as one of the project participants (in addition to the European Union, China, South Korea, the USA and Japan), is to supply nine diagnostic systems for the ITER site. These systems will be mounted in a fusion reactor that is being built in France. Diagnostic systems account for about 10% of the Russian Federation's total contribution to the project. The federal budget will allocate 50 million roubles to the institute for the project in 2013 alone; the amount could then increase several times.

"Today, it is assumed that ITER will be launched in 2020. It's now 2013, so the scale is five to seven years. The time-frame of the project will obviously be adjusted," said Krasilnikov.

"Nuclear fusion is not a dream, it's becoming a reality. We are one step away from its implementation," said Osamu Motojima, ITER Director-General. "It's obvious to me that the Institute of Nuclear Physics is an institution with a long history, where outstanding scientific research is carried out and there is a high concentration of scientific personnel that have proven their efficacy."

ВКонтакте
G+
OK
 
самое популярное
join us